Utilizing this foundational technique, CAR-T trials targeting CD3, CD5, CD7, TRBC1, and CCR4 are ongoing and possess immense potential in the treatment of T-cell lymphomas. Here, CCR4 is linked to T-cell non-Hodgkin lymphoma.